Rubin Eyal has filed 3 insider transactions across 1 company since August 2023.
Most recent transaction: a grant/award of 90909 shares of Protalix BioTherapeutics, Inc. ($PLX) on September 23, 2024.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 23, 2024 | Protalix BioTherapeutics, Inc. | $PLX | Rubin Eyal | Sr. VP and CFO | A | Common Stock | 90909 | $0.00 | 660,909.0000 | 73,308,281 | 15.95% | 0.12% |
| Sept. 23, 2024 | Protalix BioTherapeutics, Inc. | $PLX | Rubin Eyal | Sr. VP and CFO | A | Common Stock | 99010 | $0.00 | 669,010.0000 | 73,308,281 | 17.37% | 0.14% |
| Aug. 15, 2023 | Protalix BioTherapeutics, Inc. | $PLX | Rubin Eyal | Sr. VP and CFO | A | Common Stock | 201903 | $0.00 | 570,000.0000 | 83,200,641 | 54.85% | 0.24% |